期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 83, 期 2, 页码 375-381出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2020.03.075
关键词
atopic dermatitis; cancer risk; lymphoma; skin cancer; tacrolimus; topical calcineurin inhibitors
类别
资金
- Astellas Pharma
- LEO Pharma
Background: Long-term safety of topical calcineurin inhibitors is not well understood. APPLES (A Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis; NCT00475605) examined incidence of lymphoma and other cancers in a pediatric population with atopic dermatitis. Objective: To quantify incident malignancies during 10 years in children with atopic dermatitis who used topical tacrolimus for $6 weeks. Methods: Standardized incidence ratios for cancer events were analyzed relative to sex-, age-, and race-matched control data from national cancer registries. Results: There were 7954 eligible patients enrolled at 314 sites in 9 countries. During 44,629 person-years, 6 confirmed incident cancers occurred (standardized incidence ratio, 1.01; 95% confidence interval, 0.37-2.20). No lymphomas occurred. Limitations: Observational prospective cohort study. Conclusion: The cancer incidence was as expected, given matched background data. This finding provides no support for the hypothesis that topical tacrolimus increases long-term cancer risk in children with atopic dermatitis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据